Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Issue 4 (24th March 2022) - Eichenauer, Dennis A.; Bühnen, Ina; Plütschow, Annette; Kobe, Carsten; Dietlein, Markus; Wendtner, Clemens‐Martin; Thorspecken, Sven; Topp, Max S.; Mauser, Mareike; von Tresckow, Bastian; Fuchs, Michael; Borchmann, Peter; et al.